Overview

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Status:
Completed
Trial end date:
2017-07-05
Target enrollment:
Participant gender:
Summary
The aim was to assess the efficacy and safety of SD-101-6.0 cream versus Placebo (SD-101-0.0) cream in the treatment of skin lesions in participants with Epidermolysis Bullosa. Funding Source - United States Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD).
Phase:
Phase 3
Details
Lead Sponsor:
Scioderm, Inc.
Collaborators:
Amicus Therapeutics
Amicus Therapeutics, Inc.